Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate lines up execs

This article was originally published in The Tan Sheet

Executive Summary

Colgate-Palmolive announced new positions for three senior executives viewed as potential successors to CEO Reuben Mark July 9. Ian Cook will take the COO post and will head all Colgate's businesses except for Latin America and the Hill's pet food division. Javier Teruel is appointed vice chairman and will be responsible for worldwide strategy. Lois Juliber, also appointed vice chairman, will continue to head Global Business Development, R&D and other areas. All three will report to President William Shanahan. Mark noted in February he plans to retire in the next two to four years and that one of three execs "in rotational mode" would succeed him (1"The Tan Sheet" Feb. 9, 2004, p. 7)...

You may also be interested in...



Colgate Simply White Marketing Support Will Be “Modest” In 2004

Colgate-Palmolive plans to scale back U.S. marketing expenditures on its Simply White tooth whitener after sales fell short of 2003 projections, CEO Reuben Mark said during a year-end financial presentation Feb. 3

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097037

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel